Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Preclinical Characterization of ALG-094295, a Highly Potent and Orally Bioavailable Small Molecule PD-1/PD-L1 Inhibitor Targeting Dimerization, Internalization and Degradation of PD-L1

Friday, April 17, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the preclinical characterization of ALG-094295, a new small molecule PD-1/PD-L1 inhibitor. This compound is noted for its high potency and oral bioavailability, which could improve treatment adherence. It specifically targets the dimerization, internalization, and degradation of PD-L1, potentially offering a novel approach in cancer therapy.
Price reaction · baseline $7.66 (2026-04-16 close) · hit pre-market · clean, no other ALGS news in the window
day 0 close
-12.8%
day 1 · peak
-15%
day 3
-15%

Market Sentiment Analysis

POSITIVE FACTORS

  • Highly potent small molecule inhibitor developed.
  • Orally bioavailable, enhancing patient compliance.
  • Targets multiple mechanisms of PD-L1 modulation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-094295?

ALG-094295 is a highly potent small molecule PD-1/PD-L1 inhibitor.

How does ALG-094295 work?

It targets the dimerization, internalization, and degradation of PD-L1.

What are the benefits of ALG-094295?

It is orally bioavailable, which may enhance patient compliance.

What stage is ALG-094295 currently in?

The compound is in the preclinical characterization phase.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-094295 PD-1 PD-L1 cancer therapy oral bioavailability
Last updated: Apr 17, 2026

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →